EQL PHARMA AB (7JK) — Working Capital to Net Assets Ratio
EQL PHARMA AB (7JK) has a Working Capital to Net Assets ratio of 75.0% as of December 2025. Working capital of €202.36 Million (current assets of €376.73 Million minus current liabilities of €174.37 Million) is measured against net assets of €269.78 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See 7JK equity financing ratio to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
EQL PHARMA AB Working Capital to Net Assets (2022–2025)
This chart shows how EQL PHARMA AB's Working Capital to Net Assets ratio has evolved across 4 annual periods from 2022 to 2025. As of December 2025, the ratio stands at 75.0%, reflecting working capital of €202.36 Million against net assets of €269.78 Million EUR. Check EQL PHARMA AB (7JK) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for EQL PHARMA AB (2022–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for EQL PHARMA AB from 2022 to 2025, covering 4 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 7JK company net worth.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 81.1% | €179.23 Million | €221.03 Million | €400.25 Million | €221.02 Million | ▲ +61.0 pp |
| 2024 | 20.1% | €35.72 Million | €177.73 Million | €197.77 Million | €162.05 Million | ▼ -12.2 pp |
| 2023 | 32.3% | €50.04 Million | €154.75 Million | €167.23 Million | €117.19 Million | ▲ +12.4 pp |
| 2022 | 20.0% | €24.70 Million | €123.63 Million | €123.45 Million | €98.76 Million | — |